Caris Life Sciences, Inc. $CAI Shares Newly Bought by Krilogy Financial LLC

by · The Cerbat Gem

Krilogy Financial LLC bought a new stake in Caris Life Sciences, Inc. (NASDAQ:CAI – Free Report) in the third quarter, HoldingsChannel.com reports. The institutional investor bought 25,126 shares of the company’s stock, valued at approximately $746,000.

Several other institutional investors also recently bought and sold shares of CAI. NorthCrest Asset Manangement LLC bought a new position in Caris Life Sciences during the 3rd quarter worth approximately $529,000. GAMMA Investing LLC increased its stake in Caris Life Sciences by 133.0% in the 3rd quarter. GAMMA Investing LLC now owns 1,263 shares of the company’s stock worth $39,000 after purchasing an additional 721 shares during the period. Farther Finance Advisors LLC lifted its position in Caris Life Sciences by 3,888.3% in the third quarter. Farther Finance Advisors LLC now owns 5,105 shares of the company’s stock valued at $156,000 after purchasing an additional 4,977 shares during the last quarter. Whalen Wealth Management Inc. bought a new stake in Caris Life Sciences in the third quarter valued at approximately $278,000. Finally, City Center Advisors LLC bought a new stake in Caris Life Sciences in the third quarter valued at approximately $566,000.

Caris Life Sciences Stock Performance

Caris Life Sciences stock opened at $30.56 on Friday. The company has a current ratio of 5.53, a quick ratio of 4.88 and a debt-to-equity ratio of 0.66. The firm has a market cap of $8.64 billion, a P/E ratio of 84.89 and a beta of 0.86. Caris Life Sciences, Inc. has a 1-year low of $14.19 and a 1-year high of $33.13. The firm has a 50-day moving average of $27.12 and a 200-day moving average of $20.92.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on CAI. UBS Group assumed coverage on Caris Life Sciences in a research note on Wednesday, September 9th. They set a “neutral” rating and a $28.00 price objective for the company. BTIG Research lifted their target price on shares of Caris Life Sciences from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings lowered shares of Caris Life Sciences from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, October 2nd. JPMorgan Chase & Co. upped their price target on shares of Caris Life Sciences from $25.00 to $35.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, TD Cowen increased their price target on shares of Caris Life Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday. Eight investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $27.82.

Read Our Latest Stock Report on CAI

Insider Activity at Caris Life Sciences

In other Caris Life Sciences news, President David Spetzler sold 478,000 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $24.86, for a total transaction of $11,883,080.00. Following the completion of the transaction, the president owned 1,052,083 shares of the company’s stock, valued at $26,154,783.38. This represents a 31.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Brian Brille sold 400,000 shares of the company’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $30.33, for a total value of $12,132,000.00. Following the transaction, the insider directly owned 230,303 shares of the company’s stock, valued at $6,985,089.99. The trade was a 63.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,004,712 shares of company stock worth $27,205,419 in the last 90 days. Company insiders own 50.00% of the company’s stock.

Caris Life Sciences Company Profile

(Free Report)

Caris Life Sciences is a biotechnology company focused on precision oncology and the use of molecular and artificial intelligence technologies to support cancer diagnosis and treatment decisions. The company analyzes tumor and blood samples to identify genetic, molecular and other biological characteristics that may help physicians select targeted therapies and develop individualized treatment plans.

Its offerings include comprehensive tumor profiling, molecular testing and data-driven clinical support for oncologists and other healthcare providers.

Further Reading

Want to see what other hedge funds are holding CAI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Caris Life Sciences, Inc. (NASDAQ:CAI – Free Report).